Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy
Rhea-AI Summary
Benitec Biopharma (NASDAQ: BNTC) will provide a clinical update on BB-301, its gene therapy candidate for Oculopharyngeal Muscular Dystrophy (OPMD).
The company said it will report results for the six patients treated in Cohort 1 of the Phase 1b/2a study and host an investor webcast on November 3, 2025 at 8:00 am EST.
Webcast registration was posted by the company for investor access to the update.
Positive
- None.
Negative
- None.
News Market Reaction 7 Alerts
On the day this news was published, BNTC declined 3.06%, reflecting a moderate negative market reaction. Argus tracked a peak move of +41.8% during that session. Argus tracked a trough of -29.3% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $14M from the company's valuation, bringing the market cap to $429M at that time.
Data tracked by StockTitan Argus on the day of publication.
Investor webcast to be held on Monday November 3, 2025 at 8:00 am EST
HAYWARD, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced that it will provide an update on the six treated patients from Cohort 1 of its Phase 1b/2a Clinical Study of BB-301 being investigated for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD).
Webcast details:
Date: November 3, 2025
Time: 8:00 am EST
To register for the webcast, please click here.
About Benitec Biopharma Inc.
Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec’s website at www.benitec.com.
Investor Relations Contact:
Irina Koffler
LifeSci Advisors
Tel: (917) 734-7387
ikoffler@lifesciadvisors.com
FAQ
What will Benitec (BNTC) update investors about on November 3, 2025?
When and how can investors watch the Benitec (BNTC) BB-301 webcast?
Which study phase is Benitec discussing for BB-301 in OPMD?
How many patients will Benitec report on in the BB-301 Cohort 1 update?
Will the November 3, 2025 Benitec webcast include clinical data for BB-301?
